Jun-Hua Wu

Junhua Wu, Ph.D.

Professor and Director, AI for Drug Center, NIHDS
Director, Nanjing University–Gulou Joint Laboratory
Nanjing University (#62 globally (THE 2026), #70 globally (ARWU 2026), #103 globally (QS 2026)), 22 Hankou Road, Nanjing, Jiangsu 210093, China

Tel.: +86-25-83592945
Email: wujunhua@nju.edu.cn
ORCID: 0000-0003-4753-2648
Scopus Author ID: 37099360700
Personal Webpage: https://med.nju.edu.cn/wjh/main.htm

EDUCATION

·        Ph.D. (Direct Ph.D. program), 1998–2007 — Nanjing University

·        B.Sc., 1998–2002 — Nanjing University

ACADEMIC POSITIONS

·Professor (2019–Present) — Nanjing University

·Director, AI for Drug Center, NIHDS (2020–Present) —Nanjing University

·Director, Nanjing University–Gulou Joint Laboratory (2025–Present) — Nanjing University

·Associate Professor (2014–2019) — Nanjing University

·Lecturer (2007–2014) — Nanjing University

RESEARCH INTERESTS

·        Oncolytic virotherapy, Oncolytic bacterial therapy

·        Tumor biotherapy & intratumoral bacteria

·       Discovery of tumor immunotherapy targets and development of immunotherapeutic agents (antibodies, peptides, oncolytic viruses, and oncolytic bacteria)

KEY RESEARCH CONTRIBUTIONS & ACHIEVEMENTS

·        First in the world to propose the negative feedback theory of oncolytic virotherapy — a conceptual breakthrough in the field.

·    Based on this theory, developed a series of novel oncolytic viruses; the lead candidate Valpha is currently awaiting funding for clinical trials.

·   Principal Investigator of over 40 research grants, including multiple National Natural Science Foundation of China (NSFC) General Programs and Jiangsu Provincial Key R&D Programs.

·      Published over 80 SCI-indexed papers as first or corresponding author in high-impact journals including Nature Communications, Cancer Communications, Cell Reports Medicine, Cell Death & Differentiation, and Journal of Experimental & Clinical Cancer Research.

·        Over 2,400 citations in the past 5 years; h-index = 39.

·        Multiple papers selected as ESI Highly Cited Papers.

·  Supervised students to win national competition gold medals/awards for three consecutive years.

GRANTS (SELECTED)

Current Principal Investigator (totally 15 active projects):

·        Mechanisms and therapeutic strategies of oncolytic adenovirus efficacy heterogeneity via serotonin metabolic axis (NSFC General Program, 82674006)

· Intestinal microbiota in oncolytic adenovirus immunotherapy: mechanisms and combination strategies (NSFC General Program, 82272819)

·   In situ extended immune activation via oncolytic virus to control postoperative tumor recurrence (NSFC General Program, 81972888)

EDITORIAL & ACADEMIC SERVICE

Editorial Board Memberships (SCI-indexed Journals):

·        Scientific Reports (SCI) — Editorial Board Member

·        Translational Oncology (SCI) — Editorial Board Member

·        Biocell (SCI) — Editorial Board Member

·        Discovery Medicine (SCI) — Editorial Board Member

·     Molecular and Clinical Oncology (SCI) — Editorial Board Member

Professional Affiliations:

·Chinese Association of Integrative Medicine, Clinical Chinese Pharmacy Division — Executive Council Member

·China Medical Education Association, TCM Chronic Disease Prevention Engineering Committee — Standing Committee Member

·  China Medical Biotechnology Association, Oncolytic Biotherapy Committee — Committee Member

·Jiangsu Scientific Instrument and Equipment Association — Council Member

SELECTED PUBLICATIONS (AS CORRESPONDING AUTHOR)

1.    Cai Q, Zhang L, Kong L, Fang J, Xu J, Gu X, Li W, Jiang C*, Wu J*. Leveraging multimodal cancer immunotherapy to amplify the efficacy of oncolytic viruses. Experimental Hematology & Oncology, 2026. [IF=17.5, Q1 Top]

2.    Ren X, Zhou Z, Kong L, Guo Y, Liu Y, Li J, Gu X, Jiang C*, Wu J*. Re-balancing immunity with CRISPR–Cas9: novel strategies for cancer and autoimmune disorders. Biotechnology Advances, 2026, 90: 108921. [IF=14.1, Q1 Top]

3.    Yu J, Guo C, Liu Y, Ren X, Guo Y, Ran B, Xiao L, Kong L, Gu X, Jiang C*, Wu J*. The commensal microbiome in respiratory tract tumors: from oncogenic mechanisms to clinical translation. Journal of Advanced Research, 2026. [IF=17.1, Q1 Top]

4.    Guo C, Gao T, Xue B, Zhang L, Wang S, Xiao R, Kong L, Zhang Y, Xin Q, Cao Y, Gu X, Jiang C*, Wu J*. In situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence. Cell Reports Medicine, 2025, 6: 102399. [IF=14.0, Q1 Top]

5.    Ran B, Xiao L, Liu Y, Zhang C, Kong L, Zhang Y, Gu X, Jiang C*, Wu J*. Dynamic remodeling of amino acid metabolism in tumor-associated macrophages: fueling immunosuppression, reshaping tumor niches, and unlocking metabolic checkpoints. Journal of Advanced Research, 2025. [IF=17.1, Q1 Top]

6.    Zhang Y, Wang N, Zhang L, Zhuang Y, Xin Q, Gu X, Jiang C*, Wu J*. Serotonin (5-hydroxytryptamine, 5-HT): metabolism, signaling, biological functions, diseases, and emerging therapeutic opportunities. MedComm, 2025, 6(9): e70383. [IF=14.1, Q1 Top]

7.    Wang S, Kong L, Wang L, Zhuang Y, Guo C, Zhang Y, Cui H, Gu X, Wu J*, Jiang C*. Viral expression of NE/PPE enhances anti-colorectal cancer efficacy of oncolytic adenovirus by promoting TAM M1 polarization to reverse insufficient effector memory/effector CD8+ T cell infiltration. Journal of Experimental & Clinical Cancer Research, 2025, 44: 97. [IF=14.1, Q1 Top; ESI Highly Cited Paper]

8.    Wang P, Qiu J, Fang Y, Li S, Liu K, Cao Y, Zhang G, Wang Z, Gu X, Wu J*, Jiang C*. SENP3 inhibition suppresses hepatocellular carcinoma progression and improves the efficacy of anti-PD-1 immunotherapy. Cell Death & Differentiation, 2025. [IF=13.6, Q1 Top]

9.    Liu K, Kong L, Cui H, Zhang L, Xin Q, Zhuang Y, Guo C, Yao Y, Tao J, Gu X, Jiang C*, Wu J*. Thymosin alpha 1 reverses oncolytic adenovirus-induced M2 polarization of tumor-associated macrophages to improve antitumor immunity and therapeutic efficacy. Cell Reports Medicine, 2024, 5: 101751. [IF=14.0, Q1 Top]

10. Xiao L, Zhang L, Guo C, Xin Q, Gu X, Jiang C*, Wu J*. “Find Me” and “Eat Me” signals: tools to drive phagocytic processes for modulating antitumor immunity. Cancer Communications, 2024, 44(7): 791–832. [IF=28.4, Q1 Top; Top Cited Article 2025; Wiley China High Contribution Author Award Q2 2024]

11. Zhuang Y, Liu K, He Q, Gu X, Jiang C*, Wu J*. Hypoxia signaling in cancer: implications for therapeutic interventions. MedComm, 2023, 4(1): e203. [IF=14.1, Q1 Top; MedComm Top Cited Article 2023]

HONORS & AWARDS

·2026 — First Prize (Highest Award), 11th National College Biomedical Engineering Innovation Design Competition (Supervisor)

·2026 — Silver Medal, 12th National College Medical Innovation Competition & Belt & Road International Competition (Supervisor)

·2026 — Bronze Medal, 12th National College Medical Innovation Competition & Belt & Road International Competition (Supervisor)

·2025 — Top Cited Article, Cancer Communications

·2025 — Nanjing University Education-Research Integration Award

·2025 — Nanjing University Outstanding Academic Master's Thesis Award (Supervisor)

·2025 — Translational Oncology 2024 Reviewer Recognition Award

·2025 — Gold Medal, 11th National College Medical Innovation Competition & Belt & Road International Competition (Supervisor)

·2025 — Outstanding Supervisor Award, 11th National College Medical Innovation Competition

· 2024 — Wiley China High Contribution Author Award (Q2)

·2024 — Gold Medal, 10th National College Basic Medical Innovation Research Competition (Supervisor)

·2024 — Best Presentation Award, 10th National College Basic Medical Innovation Research Competition (Supervisor)

·2024 — Outstanding Supervisor Award, 10th National College Basic Medical Innovation Research Competition

·2024 — Bronze Medal, 10th National College Basic Medical Innovation Research Competition (Supervisor)

·2023 — MedComm Top Cited Article Author

BOOKS & TRANSLATIONS

·Co-author — Optimization of Lead Compounds: Functional Marine Biomolecules — Discovery and Application (with Wang J), Science Press

·Lead Translator (100,000 words) — Medical Ethics (with Li F, Qiu J), translated from Oxford University Press, Yilin Press

·Co-translator (500,000 words) — Stem Cells: Biology and Application (with Zeng Y, Jiang C, et al.), translated from CRC Press, Phoenix Science Press